Risk Factors of Venous Thromboembolism in Noncritically Ill Patients Hospitalized for Acute COVID-19 Pneumonia Receiving Prophylactic-Dose Anticoagulation

Background: Therapeutic/intermediate-dose heparin reduces the risk of thromboembolic events but increases the risk of major bleeding in patients hospitalized for acute COVID-19 pneumonia. Objectives: To prospectively assess the incidence of objectively proven venous thromboembolism (VTE) and identif...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Viruses Jg. 14; H. 4; S. 737
Hauptverfasser:	Poletto, Francesco, Spiezia, Luca, Simion, Chiara, Campello, Elena, Dalla Valle, Fabio, Tormene, Daniela, Camporese, Giuseppe, Simioni, Paolo
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Switzerland MDPI AG 31.03.2022 MDPI
Schlagworte:	Aged Anticoagulants - therapeutic use Bleeding Blood Blood platelets Body mass index Cardiovascular disease Contraindications Coronaviruses COVID-19 COVID-19 - epidemiology Creatinine Data collection Diabetes Hemoglobin Heparin Heparin - adverse effects Hospitalization Hospitals Humans Hypertension Kidney diseases Laboratories Obesity Obesity - complications Patients Pneumonia prophylactic-dose anticoagulation Retrospective Studies Risk Factors Sepsis Severe acute respiratory syndrome coronavirus 2 Thromboembolism Thrombosis venous thromboembolism Venous Thromboembolism - drug therapy Venous Thromboembolism - epidemiology Venous Thromboembolism - prevention & control Italy COVID-19 prophylactic-dose anticoagulation venous thromboembolism
ISSN:	1999-4915, 1999-4915
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!